Serologic markers in inflammatory bowel disease (IBD). (Cover Story).Inflammatory bowel disease inflammatory bowel disease
n. Abbr. IBD
Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. (IBD IBD
inflammatory bowel disease
Inflammatory bowel disease (IBD)
Disease in which the lining of the intestine becomes inflamed.
Mentioned in: Amebiasis
1. ) is a generic term that refers to Crohn's disease and ulcerative colitis. IBD is prevalent in children as well as adults. Crohn's disease (CD) is a granulomatous enteritis which may involve the ileum ileum: see intestine.
Final and longest segment of the small intestine. It is the site of absorption of vitamin B12 (see vitamin B complex) and reabsorption of about 90% of conjugated bile salts. , colon, and other parts of the intestinal tract. Crohn's disease was first reported by Burrill Crohn and his colleagues in 1922 and was called regional ileitis. (1) Crohn's disease is diagnosed in at least four patients per 100,000 in the United States, and the incidence and prevalence is rising. (2)
Ulcerative colitis (UC) is a chronic disease of unknown etiology characterized by inflammation of the mucosa and submucosa submucosa /sub·mu·co·sa/ (sub?mu-ko´sah) areolar tissue situated beneath a mucous membrane.
A layer of loose connective tissue beneath a mucous membrane. of the large intestine. The inflammation usually involves the rectum down to the anal margin and extends proximally in the colon for a variable distance. Ulcerative colitis may have a prevalence of about 100 cases per 100,000 population in the United States. (3)
Overlap of Crohn's disease and ulcerative colitis
Crohn's disease (CD) and chronic ulcerative colitis (UC) are generally considered to be distinct forms of inflammatory bowel disease (IBD). However, the symptoms and clinical presentations of CD and UC commonly overlap, and the diagnostic differentiation of cases limited to the large intestine may be problematic. (4,5) There is a subgroup of cases of CD with a UC-like presentation that illustrates the similarity of CD and UC. (5-7) A patient who may have been initially diagnosed as having UC may over time be considered as a case of CD in view of extension of the disease. (8,9)
Today, new and improved therapeutic modalities are available for CD and UC. As these various cases of IBD are treated with different types of therapeutic agents, it is important to correctly diagnose IBD and to differentiate CD from UC.
What is classically termed Crohn's disease (CD) may represent a heterogeneous group of diseases manifesting similar features. (10-13) A recent study suggests that Crohn's patients may have a heterogeneous serological serological
pertaining to or emanating from serology.
one involving examination of blood serum usually for antibody. response to specific bacteria and bacterial related antigens. (14) The serologic se·rol·o·gy
n. pl. se·rol·o·gies
1. The science that deals with the properties and reactions of serums, especially blood serum.
2. responses seen in Crohn's patients include antibodies to Saccharomyces Saccharomyces: see yeast. cerevisiae, mycobacteria mycobacteria
members of the genus Mycobacterium.
see opportunist (atypical) mycobacteria (below).
see opportunist (atypical) mycobacteria (below). , bacteriodes, listeria Listeria /Lis·te·ria/ (lis-ter´e-ah) a genus of gram-negative bacteria (family Corynebacterium); L. monocyto´genes causes listeriosis.
n. , and E. coli.
Many of the specific organisms have been proposed to directly or indirectly contribute to the pathogenesis of Crohn's disease. (14)
Irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence.
Irritable bowel syndrome (IBS IBS Irritable bowel syndrome, see there ) is the most common functional disorder of the gastrointestinal tract. The hallmark of IBS is abdominal pain or discomfort associated with a change in the consistency or frequency of stools. (15,16) IBS is differentiated from IBD, as IBD is associated with an inflammatory response. IBS occurs at a frequency of 8 percent to 23 percent in adults in the Western world. (10,16) For IBS, there is at present no specific diagnostic laboratory test and there is an absence of definite biological markers. The diagnosis of IBS is based on a constellation of symptoms. An international consensus group has developed criteria for IBS in an effort to standardize the definition of IBD. (12,18) The criteria have been termed the "Rome Criteria" in reference to the location of the meeting. The criteria have been further refined. (15)
Immune markers associated with IBD
During the past few years, several investigators have identified diagnostic serological markers for UC and CD. Drs. S. Targan and J. Braun and their respective groups of investigators have made a significant contribution. The serologic markers discussed below have been found to be useful for the diagnosis and differentiation of CD and UC. In addition, a panel of markers with use of an algorithm can identify specific subtypes of IBD that have different progressions and clinical courses. Thus, the panel of serologic markers are useful for diagnosis and management of CD and UC patients.
Classification of serum immune markers in IBD
Currently the following serum immune markers have found to be useful for giagnosis and management of IBD. (19-23) (see Chart 1)
1) Deoxyribonuclease deoxyribonuclease /de·oxy·ri·bo·nu·cle·ase/ (DNase) (-ri?bo-noo´kle-as) any nuclease catalyzing the cleavage of phosphate ester linkages in deoxyribonucleic acids (DNA); separated by whether they cleave internal bonds or bonds at termini. (DNase I) sensitive perinuclear perinuclear /peri·nu·cle·ar/ (-noo´kle-ar) near or around a nucleus. antineutrophil cytoplasmic autoantibody autoantibody /au·to·an·ti·body/ (-an´ti-bod?e) an antibody formed in response to, and reacting against, an antigenic constituent of one's own tissues.
n. (pANCA) associated with IBD. The IBD associated pANCA defines an antibody to a nuclear antigen which is sensitive to DNase I.
2) ASCA ASCA American School Counselor Association
ASCA Australian Shepherd Club of America
ASCA Arab Society of Certified Accountants
ASCA American Swimming Coaches Association
ASCA American Society of Consulting Arborists
ASCA Association of State Correctional Administrators (Anti-Saccharomyces cervisiae antibody). (21,26) This antibody is present in the serum of up to 70 percent of Crohn's disease patients.
3) Pancreatic antibody. (27-29) This antibody is observed in approximately 30 percent of Crohn's disease patients. Two distinct staining patterns have been reported.
4) Anti-OmpC (outer membrane porin Porin can be:
Significance of ANCAs
(Anti neutrophilic neutrophilic /neu·tro·phil·ic/ (-fil´ik)
1. pertaining to neutrophils.
2. stainable by neutral dyes.
1. pertaining to neutrophils.
2. stainable by neutral dyes. cytoplasmic antibody)
* ANCAs associated with vascular diseases (vasculitidies). ANCAs are autoantibodies directed against the intracellular components of the neutrophils neutrophils (ner·ō·trōˑ·filz),
n.pl white blood cells with cytoplasmic granules that consume harmful bacteria, fungi, and other foreign materials. . Over the past decade, ANCA ANCA Armenian National Committee of America
ANCA Anti-Neutrophil Cytoplasmic Antibody (medical)
ANCA Australian National Choral Association
ANCA Australian Nature Conservation Agency
ANCA Airport Noise and Capacity Act has received considerable attention as it was seen in inflammatory vasculitides. (32-35) The key antigen in the cytoplasm of neutrophils was found to be scrine proteinase proteinase /pro·tein·ase/ (pro´ten-as?) endopeptidase.
A protease that begins the hydrolytic breakdown of proteins usually by splitting them into polypeptide chains. 3 . (36) The staining of ANCA reaction with proteinase 3 will result in a cytoplasmic fluorescent pattern called c-ANCA. The pANCA pattern of perinuclear staining around the nuclei of neutrophils is the second type of pattern noted. The pANCA pattern is the result of positively charged molecules that migrate to the edge of the nuclei of neutrophils. This phenomenon occurs after alcohol fixation of the sub-state cells. The cytoplasmic granules Granules
Small packets of reactive chemicals stored within cells.
Mentioned in: Allergic Rhinitis, Allergies redistribute around the nuclei, resulting in a pANCA pattern in case of antibodies to elastase elastase /elas·tase/ (e-las´tas) see pancreatic elastase.
An enzyme found especially in pancreatic juice that catalyzes the hydrolysis of elastin. , lactoferrin lactoferrin
n an iron-binding protein found in the specific granules of neutrophils where it apparently exerts an antimicrobial activity by withholding iron from ingested bacteria and fungi. , cathepsin cathepsin /ca·thep·sin/ (kah-thep´sin) one of a number of enzymes each of which catalyzes the hydrolytic cleavage of specific peptide bonds. G, and myeloperoxidase. The pANCA pattern with myeloperoxidase is significant since antibodies to myelo-peroxi dase may be seen in vasculitis Vasculitis Definition
Vasculitis refers to a varied group of disorders which all share a common underlying problem of inflammation of a blood vessel or blood vessels. The inflammation may affect any size blood vessel, anywhere in the body. . (36) Antibodies to serine serine (sĕr`ēn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer appears in mammalian protein. proteinase 3 and myeloperoxidase maybe specifically detected by an ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent.
n. (enzyme linked immunosorbent immunosorbent /im·mu·no·sor·bent/ (-sor´bent) an insoluble support for antigen or antibody used to absorb homologous antibodies or antigens, respectively, from a mixture; the antibodies or antigens so removed may then be eluted in pure assay).
* Association of ANCA with inflammatory bowel disease. IBD associated ANCA was first reported in 1966 by Faber and Elling, who described "leukocyte-specific antinuclear antibodies" in patients with Crohn's disease and ulcerative colitis. (38) It is now clear that the granulocyte granulocyte /gran·u·lo·cyte/ (gran´u-lo-sit?) granular leukocyte.granulocyt´ic
band-form granulocyte band cell.
n. specific antinuclear antibodies are in fact pANCA. (39) Many investigators have subsequently noted the association of pANCA with IBD. (5,10,25,39) The reported incidence of serum ANCA in UC patients was reported to be between 50 and 80 percent. (19-23) Serum pANCA is believed to reflect mucosal pANCA production in some instances. Studies have shown that pANCA production takes place in the colonic mucosa. (19,20) It appears that the mucosal antigens lead to local production of pANCA in the intestinal tact.
* pANCA associated with ulcerative colitis. The majority of adult patients with UC (60 percent to 80 percent) exhibit a positive test for pANCA. (19) Also pANCA has been observed in 83 percent of children. (19) Billing et al. have provided evidence that the pANCA antigen associated with UC is nuclear in location. (40) They studied the neutrophil neutrophil /neu·tro·phil/ (noo´tro-fil)
1. a granular leukocyte having a nucleus with three to five lobes connected by threads of chromatin, and cytoplasm containing very fine granules; cf. heterophil.
2. reaction with confocal confocal
see confocal microscopy. and electron microscopy and demonstrated that the UC-associated pANCA reaction was localized primarily over chromatin chromatin: see chromosome. concentrated toward the periphery of the nuclei. (40) The UC patients' sera also did not recognize double stranded DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . There may be multiple antigens and epitopes involved in the atypical pANCA and it has been reported as associated with histone-1, (41, 42) high mobility group nuclear protein (HMG-1 and HMG-2), (43, 44) and more recently as a 50 kilodalton nuclear envelope protein. (45)
The pANCA pattern seen in IBD is the result of nuclear antigens which are DNase I sensitive. The pANCA staining pattern is lost after the DNase I digestion of the substrate cells. In approximately 70 percent of the cases of UC, there is ablation of the pattern and antigen recogmtion, and in up to 30 percent of the cases there is conversion to homogeneous cytoplasmic staining. (19-23) In 3 percent ofUG patients evaluated displaying pANCA reactivity, the pANCA pattern was retained after DNase treatment of the substrate.(19-23) The retained pattern may represent concurrent antibodies present to cytoplasmic or nuclear antigens other than the IJC IJC International Joint Commission
IJC Internet Journal of Chemistry
IJC International Journal of Cancer
IJC International Court of Justice
IJC Independent Journalism Centre
IJC International Journal of Climatology
IJC International Journal of Control associated pANCA antigen. ANCAs are present in the sera of 60 percent to 80 percent of patients with ulcerative colitis and 10 percent to 30 percent of patients with Crobn's disease. Eighty-three percent of children and adolescents with ulcerative colitis showed the expression of ANCA in their sera. (23)
Various studies have shown that UC patients with pANCA represent subpopulations which show production of pANCA. This may be consequence of a distinct mucosal inflammatory process.
What does the expression of pANCA mean in patients with UC?
The pANCA expression allows for stratification of the TiC patients at the clinical and genetic levels. In adults, clinically distinct subsets of UC have been observed based on the presence of ANCA/pANCA as these patients have a higher probability of:
* Having more aggressive disease.
* Having left-sided ulcerative colitis which is more resistant to treatment than the usual case.
* Requiring surgery early in the course of the disease.
* Developing pouchitis in TiC following ileal ileal /il·e·al/ (il´e-ahl) pertaining to the ileum.
Of or relating to the ileum.
pertaining to the ileum. pouch-anal anastomosis anastomosis /anas·to·mo·sis/ (ah-nas?tah-mo´sis) pl. anastomo´ses [Gr.]
1. communication between vessels by collateral channels.
* Having specific HLA HLA human leukocyte antigens.
human leukocyte antigen
HLA (human leuckocyte antigen) markers.
The serum pANCA in UC patients may reflect mucosal pANCA production. This suggests that recognition of mucosal antigens leads to local production of pANCA.
Targan and Braun and co-workers have recently demonstrated the presence of specific bacterial and/or bacteria-like antigens in patients with Crohn's disease and ulcerative colitis that appear to elicit antibody response in those patients. (30, 31)
With the use of phage display technology monoclonal antibodies that cross-react with antigens that are similar to those seen in sera of UC patients who are pANCA positive. These monoclonal antibodies cross react with bacterial antigens from E. coli and bacteriodes. (30)
Segregation of pANCA by DNase I treatment to differentiate ulcerative colitis from Type I autoimmune hepatitis and primary sclerosing cholangitis Primary sclerosing cholangitis
A chronic disease in which it is believed that the immune system fails to recognize the cells that compose the bile ducts as part of the same body, and attempts to destroy them.
UC associated ANCA yields a perinuclear staining pattern pANCA with methanol fixed neutrophils. pANCAs have been detected in the serum of patients with autoimmune hepatitis (Type I AIH AIH American Institute of Homeopathy; artificial insemination by husband.
1. artificial insemination performed by the husband
2. ), primary sclerosing cholangitis (PSC (Public Service Commission) Same as PUC. ), and other autoimmune liver diseases.
The pANCA pattern has been identified in about 70 percent of ulcerative colitis (UC) patients. Also, the pANCA pattern with alcohol fixed neutrophils has been reported in 92 percent of sera from patients with well-defined Type I autoimmune hepatitis. Furthermore, the pANCA pattern was noted in up to 70 percent of PSC patients.
The pANCA associated with UC reactive antigen was associated with epitopes within the nuclei. In addition, the UC pANCA demonstrated loss of antigenic recognition after DNase I enzyme digestion of neutrophils as a dominant feature.
In direct contrast, the majority of Type I autoimmune hepatitis and PSC patients showed a pANCA pattern recognizing cytoplasmic constituents. Thus, the UC associated pANCA with epitopes within the nuclei is highly specific for inflammatory bowel disease. (45,46)
Association of serum pANCA with subgroup of Crohn's disease
The serum pANCA are seen in 10 percent to 30 percent of patients who have diagnosed as having CD. (19) In CD, expression of pANCA identifies a subgroup of CD characterized as "ulcerative ulcerative /ul·cer·a·tive/ (ul´se-ra?tiv) (ul´ser-ah-tiv) pertaining to or characterized by ulceration.
pertaining to or characterized by ulceration. colitis-like" phenotype in which patients have clinical features of left-sided colitis with histopathologic features of UC. The serum immunoglobulin IgG (immunogloulin G) of pANCA positive CD patients is similar to the pANCA seen with UC patients. The presence of pANCA in both CD and UC suggests that there is a specific type of mucosal inflammation that may be common to CD and UC. (19,27,48)
The CD patients who are pACNA positive did not respond as well as the majority of CD patients to anti-TNF (tumor necrosis factor tumor necrosis factor
n. Abbr. TNF
A protein that is produced in the presence of an endotoxin, especially by monocytes and macrophages, is able to attack and destroy tumor cells, and exacerbates chronic inflammatory diseases. ) monoclonal antibody therapy Monoclonal antibody therapy is the use of monoclonal antibodies (or Mab) to specifically target cells. The main objective is stimulating the patient's immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors. . On the other hand, 65 percent of Crobn's disease patients responded well to anti-TNF monoclonal antibody therapy. (19)
High levels of pANCA in Crohn's disease patients were associated with later age of onset The age of onset is a medical term referring to the age at which an individual acquires, develops, or first experiences a condition or symptoms of a disease or disorder.
Diseases are often categorized by their ages of onset as congenital, infantile, juvenile, or adult. and an UC-like inflammatory response, as well as a relative decreased incidence of fibrostenosis and penetrating disease. (22)
Method of assay for serologic markers in IBD
* Indirect Immunofluorescence Assay for ANCA. (25)
Neutrophils were isolated from peripheral blood of normal persons by Ficoll-Hypaque density centrifugation Centrifugation
A mechanical method of separating immiscible liquids or solids from liquids by the application of centrifugal force. This force can be very great, and separations which proceed slowly by gravity can be speeded up enormously in centrifugal followed by dextran dextran /dex·tran/ (dek´stran) a high-molecular-weight polymer of d-glucose, produced by enzymes on the cell surface of certain lactic acid bacteria. sedimentation. (49)
The neutrophils were resuspended in phosphate buffered saline Phosphate buffer saline (abbreviated PBS) is a buffer solution commonly used in biochemistry. It is a salty solution containing sodium chloride, sodium phosphate and potassium phosphate. The buffer helps to maintain a constant pH. (PBS PBS
in full Public Broadcasting Service
Private, nonprofit U.S. corporation of public television stations. PBS provides its member stations, which are supported by public funds and private contributions rather than by commercials, with educational, cultural, ), and 100,000 cells were prepared on slides by cytocntrifugation. The slides were fixed in 100 percent methanol at 4[degrees]C for 10 minutes, air dried, and stored at -20[degrees]C. After incubation of the sera on the slides for 20 minutes, the slides were washed in PBS and stained with fluorescein-labeled F[(ab').sub.2] gammachain specific antibody. After washing, the slides were examined by fluorescence microscopy.
* Formalin formalin /for·ma·lin/ (for´mah-lin) formaldehyde solution.
An aqueous solution of formaldehyde that is 37 percent by weight. fixation and pitcalls in the assay for ANCA. (50)
The British Association of Clinical Pathologists suggested that formalin acetone acetone (ăs`ĭtōn), dimethyl ketone (dīmĕth`əl kē`tōn), or 2-propanone (prō`pənōn), CH3COCH3 fixation followed by absolute ethanol may be useful to differentiate pANCA from ANA. (51) This procedure has not been confirmed by international consensus. Lee et al. (52) suggested that formaldehyde vapor fixation may be used to detect conversion of pANCA (pattern noted by alcohol fixation) to the cytoplasmic pattern when myeloperoxidase antibodies were present. However, Lee et al. found that formalin acetone fixation gave inconsistent results. (52) Other studies have shown that formalin fixation caused inconsistency; nonspecific effects and false positivity owing to enhanced fluorescence. (53)
In some cases neutrophils were incubated with the pANCA positive sera and the F[(ab').sub.2] gamma-chain specific antibody before DNase I digestion of the slides.
The pANCA which are DNase I sensitive are characteristically seen in UC patients and CD patients. When the pANCA pattern is observed in UC patients and treated with DNase I, in 70 percent there is ablation of antigen recognition, and in 30 percent there is conversion to a homogeneous pattern. (19)
* Fixed neutrophil ELISA assay for ANCA. The assay has been described by Saxon et al. (25) The microtiter plates were coated with 2.5 x [10.sup.5] meutrophils per well. These were fixed in methanol for 10 minutes and allowed to air dry. To minimize nonspecific nonspecific /non·spe·cif·ic/ (non?spi-sif´ik)
1. not due to any single known cause.
2. not directed against a particular agent, but rather having a general effect.
1. binding, 0.25 percent bovine serum albumin was added as a blocking agent.
The control patients' sera were added to different wells at dilution of 1:100. The neutrophil bound antibody was detected by alkaline phosphatase conjugated conjugated
estrogens, conjugated Warning - Hazardous drug!
C.E.S. goat anti-human IgG. After addition of p-nitrophenol, specific absorbance absorbance /ab·sor·bance/ (-sor´bans)
1. in analytical chemistry, a measure of the light that a solution does not transmit compared to a pure solution. Symbol .
2. was read at 405 nm. The levels of ANCA are determined relative to a laboratory standard expressed as ELISA Units (EU/mL). The standard was obtained from sera of pANCA positive patients with well-characterized UC.
* ELISA assay for ASCA in CD patients. (22,48) The microtiter plates were coated with phosphopeptidomannans from the yeast Saccharomyces cerevisiae ssp uvarum. The control and patients' serum samples were added to different wells at a 1:100 dilution. Bound antibodies were detected with goat anti-human IgG and IgA labeled with alkaline phosphatase. After adding p-nitrophenol, the specific absorbance was measured at 405 nm. The absorbance of each serum sample was evaluated and assigned ELISA Units (EU/mL) values relative to the absorbance of a pool of sera collected from well-characterized patients with CD. The standard pool was arbitrarily assigned the value of 100 EU/mL. The result of the CD diagnostic system panel determines relative positivity of IgA and IgG ASCA respectively.
* IBD first step screen for ANCA, IgG ASCA IgA ASCA and IgA anti OmpC. Prometheus Laboratories developed quantitative tests that detect serum markers consistent with the presence of IBD. (54) This IBD First Step system consists of a set of four quantitative ELISA assays used together to detect ANCA, IgG ASCA IgA ASCA and IgA anti OmpG antibodies. The panel of assays shared a test sensitivity of 94 percent. The negative predictive value The negative predictive value is the proportion of patients with negative test results who are correctly diagnosed. Worked example
(as determined by "Gold standard")
True False is greater than 95 percent when the data is modeled for an IBD prevalence commonly seen in a standard gastroenterology practice of 15 percent. The tests have a high sensitivity, but a much lower specificity. The main purpose of the test panel is to help rule out the presence of IBD. The algorithm with use of the sensitive modified assay is shown in Chart 2. The algorithm can be applied to children, adolescents and adults with IBD.
* Variability of assays for ANCA and ASCA in different clinical laboratories. Sandborn, W.J. et al. (55) conducted a study with the purpose of evaluating serological markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Blood and sera were obtained from 162 patients who agreed to participate in the study from a group of 290 IBD patients. Of the 162 patients, 83 had ulcerative colitis and 79 had Crohn's disease. The conclusions reached by the Sandborn et al. study:
1) The sensitivity of the ANCA assays varied widely in different laboratories.
2) The prevalence of ASCA was similar in the various laboratories participating in the study.
3)The positive predictive values of the ANCA and ASCA for the diagnosis and evaluation of UC or CD are high enough to be clinically useful.
Antibodies associated with Crohn's disease
Besides the pANCA that identifies a subgroup population of Crobn's disease, there are several other antibodies that are associated with Crohn's disease. These antibodies include Saccharomyces cerevisiae antibody (ASCA), pancreatic antibody, and antibody to OmpC (outer membrane porins isolated from E. coli bacteria).
ASCA is a serum immune marker, which has been shown to be expressed in the majority of sera of CD patients. (22,23,48) The ASCA antibodies have a high specificity for Crohn's disease. (22,48) Serum ASCA is expressed in up to 70 percent of CD patients.
Small bowel disease was present in almost all CD patients who were positive for both IgA and IgG ASCA but negative for pANCA. The majority of patients in the subgroup may have signs of small bowel obstruction and perforating disease. The CD patients with IgA ASCA and IgG ASCA appear to have a more aggressive type of CD.
The ASCA assay is performed by an ELISA method. It should be emphasized that negative tests of pANCA or serum ASCA do not rule out the presence and diagnosis of IBD. The positive tests provide evidence that the patients with IBD should be evaluated further. (48,52)
An ASCA ELISA with lower threshold was able to detect 90 percent of diagnosed Crohn's disease patients. V/hen evaluated at the lower threshold to allow exclusion of IBD as a probable diagnosis for negative samples, a positive result must be followed up with more specific test to allow probable diagnosis of IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) . (52)
Pancreatic antibodies in Crohn's disease
Pancreatic antibodies as detected by an indirect immuno-fluorescence test with human pancreas substrate occurred in 31 percent to 39 percent in Crohn's disease patients. (27) Of 212 CD patients studies, 30 patients had pancreatic antibodies characterized by a "drop-like" fluorescence in the pancreatic acini acini Plural of acinus, eg, milk-producing glands of breast (subtype I). (28,29) Twenty-eight patients demonstrated a fine speckled staining in the acinar cells of the pancreas (subtype II). (28,29) Siebold et al. (28) concluded that pancreatic antibodies are specific markers for CD. Two subgroups were seen with different immunofluorescent immunofluorescent
having the characteristic of immunofluorescence.
immunofluorescent antibody test
see fluorescence microscopy.
see fluorescence microscopy. patterns.
It remains to be determined whether the presence of the pancreatic, antibody is associated with a defined sub group of CD patients. The specific antigen reacting with the pancreatic antibody has not been identified. These antibodies were rarely seen to occur in family members of patients with Crohn's disease.
The relevance of pancreatic antibodies in the pathogenesis of Crohn's disease is unclear. Stocker, et al. have reported that in patients with CD diagnosed for less than 2.5 years, the prevalence of pancreatic antibodies was 25 percent. However, if the CD existed longer than 2.5 years, the incidence of pancreatic antibodies was 46 percent.
Whether the presence of pancreatic antibodies in CD identifies a subgroup of Crohn's patients remains to be determined.
The previous reports used a substrate of human type o negative pancreatic tissue. One may be able to employ primate pancreatic tissue substrate. Siebold, et al. have observed that pancreatic tissue from rats and mice showed immunofluorescent patterns similar to that observed in human. Extensive comparative data of humans and rat tissue runs waas not presented.
OmpC antibody in Crohn's disease
OmpC is an outer membrane porin antigen purified from E. coli. (30) ELISA assay with human sera demonstrated elevated IgG anti-OmpC in ulcerative colitis patients compared to healthy controls.
Cohavy et al. (30) performed experiments on the hypothesis that pANCA identifies a bacterial antigen found in the human colonic mucosa. In these experiments a monoclonal pANCA antibody was used. (30) The ANCA monoclonal antibody was cloned by a phage display method and characterized.
The pANCA monooclonal antibody was reactive with bacterioides and E. coli antigens. The E. coli protein was biochemically and genetically identified as the outer membrane porin OmpC.
In patients with Crohn's disease, IgA response to OmpG was found in 55 percent of 151 patients, 56 percent were seropositive seropositive /se·ro·pos·i·tive/ (-poz´i-tiv) showing positive results on serological examination; showing a high level of antibody.
adj. to ASCA, and 24 percent were positive with the pANCA test.
The serological response to the OmG and panel of antigens studies by Landers et al. (31) identified more Crohn's patients. There may be patient subsets of Crohn's that demonstrate variable responses to selected bacterial antigens.
Inflammatory bowel disease (IBD) is a generic term that refers to Crohn's disease and ulcerative colitis. Crohn's disease (CD) is a granulomatous enteritis which can involve the ileum, colon, and other parts of the intestinal tract. The serologic responses seen in Crohn's disease include antibodies to Saccharomyces cercvisiae, mycobacteria, bacteroides, listeria and E. coli. Many of these organisms may be involved in the pathogenesis of the Crohn's disease.
Ulcerative colitis is characterized by inflammation of the mucosa and submucosa of the large intestine.
The CD and UC are considered to be distinct forms of IBD; however, there is a subgroup of CD with a UC-like presentation.(34)
In recent years, several serologic markers have been found to be useful for the diagnosis and differentiation of CD and UC. These markers include the following antibodies (a) pANCA, (b) ASCA, (c) pancreatic antibody, and (d) 0mpC antibody. The application of a panel of markers with the use of an algorithm can identify specific subtypes of IBD that have different clinical courses and progression of the diseases. The application of the serologic markers is useful for diagnosis and management of CD and UC patients.
Dr. Robert M. Nakamura serves as Laboratory Medical Director at Prometheus Laboratories in San Diego, CA. Mary Barry is Vice-president of Operations at Prometheus Laboratories, a small volume laboraatory serving gastrointestinal specialists throughout the U.S.
(1.) Crohn BB, Ginsberg L, Oppenheimer GD. Regional ileitis, a pathological and clinical entity. JAMA JAMA
Journal of the American Medical Association 1932; 99:1323.
(2.) Rosenberg H. Crohn's disease. In: Cecil Textbook of Medicine 7th Edition WB Saunders Co. Philadelphia PA. eds Wyngaarden JB and Smith LH, Jr. 1992: 711-719.
(3.) Rosenberg H: Ulcerative colitis. In: cecil Textbook of Medicine 7th Edition WB Saunders Co. Philadelphia PA. eds Wyngaarden JB and Smith LH, Jr.,: 1992: 703-711.
(4.) Hodgson HJF HJF Henry Jackson Foundation (Rockville, MD) : Ulcerative colitis verses Crohn's disease - one disease or two? In: Inflammatory bowel diseases. 3rd Edition. Churchill Livingstone, NewYork. ods Allan RN, Rhodes JM, Hanauer SB, Keighley MRB MRB Malaysian Rubber Board
MRB Material Review Board
MRB Maintenance Review Board (Commercial Aircraft Industry and FAA)
MRB Medical Review Board
MRB Mortgage Revenue Bonds (secondary mortgage financial instrument) , Alexander Williams J, Fazio VW. 1997: 343-347.
(5.) Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang A, Rotter Jl, Vidrich A, Targan SR. Perinuclear antinoutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996: 110:1810-1819.
(6.) Seidman EG. Inflammatory bowel diseases. In: Pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children.
Of or relating to pediatrics. Gastrointestinal Disease. 4th Edition Mosby. St. Louis. eds Roy C, Silverman A. Alagille D. 1996:585-605.
(7.) Evan CM, Beattie RM, Walker-Smith JA. Inflammatory bowel disease in childhood. In: Inflammatory bowel diseases, 3rd Edition. Churchill Livingsone, New York. eds Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander Williams J, Fasio VW. 1997: 343-347.
(8.) Moum B, Ekbem A, Vatn MH, Aadland E. Sauar J, Lygen Schulz T. Stray N, Fauna 0. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in southeastern Norway. Gut 1997:40:328-332.
(9.) Seidman E, Deslandres. Pitfalls in the diagnosis and management of pediatric IBD. In: Inflammatory bowel disease and recurrent abdominal pain. Folk Symposium 91. Kluwer Academic. Lancaster, England. Hadziselimovic F, Herzog B, eds. 1997:111-120.
(10.) Targan S, Murphy LK. Serologic end mucosal markers of ulcerative colitis and Crohn's disease: Implications of pathophysiology pathophysiology /patho·phys·i·ol·o·gy/ (-fiz?e-ol´ah-je) the physiology of disordered function.
1. for diagnesis. In: Inflammatory bowel diseases-pathophysiology as a basis of treatment Kluwer Academic Publishers. Dordrecht. Eds. Scholmerich J. Kruis W, Goebell H, et al. 1993:283-6.
(11.) Retter Jl. Yang H: Delineating the major aetiological AE`ti`o`log´ic`al
a. 1. Pertaining to ætiology; assigning a cause.
Adj. 1. aetiological - of or relating to the philosophical study of causation
aetiologic, etiologic, etiological
2. risk factors for IBD: the genetic susceptibilities. In: Inflammatory bowel diseases-pathophysiology as a basis of treatment. Kluwer Academic Publishers. Dordrecht. ads Scholmerich J, Krus W. Goebell H, et al. 1993:9-18.
(12.) Satsangi J. Jewell DP, Rosenberg WMC WMC Winter Music Conference
WMC Weill Medical College (Cornell University)
WMC Wisconsin Manufacturers and Commerce (Madison, WI)
WMC Westchester Medical Center
WMC Western Mining Corporation , et al.: Genetics of inflammatory bowel disease. Gut 194;35:696-700.
(13.) Yang H, Rotter Jl: The genetics of inflammatory bowel disease: genetic predispositions, disease markers, and genetic heterogeneity. In: Inflammatory bowel disease: from bench to bedside. Williams and Wilkins. Baltimore. eds Targan SR. Shanahan F. 1994:32-64.
(14.) Landers CJ, Cohavy O, Misra R. Yang H. Lin S. Braun J, and Targan SR. Selected. net global, loss of tolerance evidenced by Crohn's disease-associated immune responses to auto and individual bacterial antigen. In press.
(15.) Rothstein RD. Irritable bowel syndrome. Advances in Gastroenterology 2000; 84:1247-1257.
(16.) Ringel Y, Sperber AD, Drossmon DA. Irritable bowel syndrome. Ann Rev Med 2001;52:319-330.
(17.) Manning AP Thompson WG, Heaton KW: Toward a positive diagnosis of the irritable bewel. BMJ BMJ n abbr (= British Medical Journal) → vom BMA herausgegebene Zeitschrift 1978:2:653.
(18.) Thompson WG,. Longstreet CE. Droasman DA: Functional bowel disorders and functional abdominal pain. Gut 1999;2 1143.
(19.) Vasiliauskas E. Serum Immune Markers in Inflammatory Bowel Disease. Gastroenterology and Endoscopy endoscopy
Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the News October 1997.
(20.) Ruemmele FM. Targan SR. Levy G, Dubinsky M. Braun J, and Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998:115:822-829.
(21.) Targan SR: The utility of ANCA and ASCA in inflammatory bowel disease. In: Inflammatory Bowel Disease. Lippincott, William and Wilkins. eds. Banks P. and Present D.1999:5:61-63.
(22.) Vasiliauskas EA, Kam LY, Karp LC. Gaiennia J, Yang H, and Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous sub-groups with distinct clinical characteristics. Gut 2000;47:487-496.
(23.) Dubinsky M, Ofman JJ. Urman, Targan SR and Siedman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am.J. of Gastroenterology 2001;46:758-765.
(24.) Shanahan, F. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterolagy, 1992:103(2),707-711.
(25.) Saxon A, Shanahan F. Landers C, Ganz T, and Targan SR. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. of Allergy and Clin. Immunol. 1999; 86:202-206.
(26.) Vermeiro S, Joossens S, Peeters M, Monsuur F, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001:120:827-833.
(27.) Stocker M, Otte S, Ulrich D, Norman H, et al. Autoimmunity to pancreatic juice in Crohn's disease. J. Gastroenterology l987;22(suppl)139,41-52.
(28.) Seibold P. Weber H, Jonas H, Wiedmann KH. Antibodies to a trypsin trypsin, enzyme that acts to degrade protein; it is often referred to as a proteolytic enzyme, or proteinase. Trypsin is one of the three principal digestive proteinases, the other two being pepsin and chymotrypsin. sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991:32:1192-1197.
(29.) Seibold P. Mork H, Tanza S, Muller A. Holzhuter P. Weber P. Scheurlen M. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997:40:481-484.
(30.) Cohavy G, Bruckner D, Gordon L Misra R, Wei B, Eggena ME. Targan SR. and Braun J. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope epitope: see immunity. . Infection and Immunity Infection and Immunity is an academic journal published by the American Society for Microbiology. The title is commonly abbreviated IAI and the ISSN is 0019-9567 for the print version, and 1098-5522 for the electronic version. , Mar 2000;68(3):1542-1548.
(31.) Landers CJ, Cohavy D, Misra R. Yang H, Lin S. Braun J, and Targan SR. Selected, not global, loss of tolerance evidenced by Crahn's disease-associated immune responses to auto and individual bacterial antigen. In press.
(32.) McCallum RM. Bylund DJ. Vasculitis. In: Clinical Diagnosis and Management by Laboratory Methods. 20th Edition W.B. Saunders Co Philadelphia PA. eds Henry JB. 2001: 990-999.
(33.) Conn DL, Hander GG, O'Duffy JD. Vasculitis and related disorders. In: Vasculitis and related disorders. 4th Edition W.B. Saunders Co. Philadelphia PA. ads Kelly WN, Harris ED Jr. Ruddy S, Sledge CB: 1993: 1077-1102.
(34.) Folk RJ, Jennette JC: Anti-neutrophilic cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing necrotizing /nec·ro·tiz·ing/ (nek´ro-tiz?ing) causing necrosis.
Causing the death of a specific area of tissue. Human bites frequently cause necrotizing infections. and cresentric glomerulonephritis glomerulonephritis: see nephritis. . NEJM NEJM New England Journal of Medicine 1988; 318:1651-1657.
(35.) Jennette JC, Falk RJ. Vasculitis. In: The Autoimmune Diseases 3rd Edition Academic press, San Diego, CA. eds Rose NR, Mackay IR. 1998: 705-724.
(36.) Jennette JC, Hoidal JR. Folk RJ. Specificity of ontineutrophilic cytoploamic antibodies for proteinase 3. Blood 1999: 75:2263-2264.
(37.) Faber V. Elling P. Leucocyte-specific Antinuclear Factor in Patients with Felty's syndrome, rheumatoid arthritis, systemic lupus erythematosis and other diseases. Acta Med. Scand. 1967: 179:257-267.
(38.) Neilsen H, Wilk A, Elmgreen J. Granulocyte specific antinuclear antibodies in ulcerative colitis. Acra Pathol. Microbial microbial
pertaining to or emanating from a microbe.
the breakdown of organic material, especially feedstuffs, by microbial organisms. . Immunol. Scand. 1993: 91:23-26.
(39.) Jennette JC, Folk RJ. Antineutrophilic cytoplasmic Autoantibodies in Inflammatory Bowel Disease. Am. J. of Clin. Path. 1993; 99:221-223.
(40.) Billing P. Tahir S, Clfin B, Gagne G, Cobb 1, Targan SR. and Vidrich A. Nuclearlocalization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am. J. of Path. 1995:147:979-987.
(41.) Cohavy O, Eggena MP, Parseghian M, Hamkalo B, Targan SR, Gordon LK. Braun J. Histone histone (hĭs`tōn), any of a class of protein molecules found in the chromosomes of eukaryotic cells. They complex with the DNA (see nucleic acid) and pack the DNA into tight masses of chromatin, which have the structure of coiled coils, much Hi, a candidate pANCA antigen in ulcerative colitis (abstr). Gastroenterology 1997: 112:A951.
(42.) Eggena M, Cohavy O Parseghian MN, Hamkalo BA, Clemens D. Targan SR, Gordon LK, Braun J. Identification of histone Hl as a cognate cognate
describes two biomolecules that normally interact such as an enzyme and its normal substrate or a receptor and its normal ligand.
cognate cooperation antigen of the ulcerative collitis-associated marker antibody pANCA. J Autoimmun. Feb 2000; 14(1):83-97.
(43.) Sobajima J. Ozaki S, Uesugi S, Osakada HF, Shirakawa H Yoshida M, Nakao K: Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (pANCA directed against HMG hMG menotropins (human menopausal gonadotropin).
human menopausal gonadotropin 1 and MG2 in ulcerative colitis (UC). Clin Exp lmmunol 1998; 111:402-407.
(44.) Sobajima J, ozaki S. Uesugi H, Osakada F, lnoue M, Fukuda Y, Shirakawa H. Yoshida M, Rokuhara A, Imal H, Kiyosawa K. Nakao K: High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplsmic antibodies in autoimmune hepatitis. Gut 1999:44:867-873.
(45.) Terjung B, Spengler U. Sauerbruch T, Worman H. "Atypical pANCA" in IBD and hepatobiliary disorders react with a 50 kilodalton nuclear envelope protein of neatrophils and myeloid myeloid /my·eloid/ (mi´e-loid)
1. medullary; pertaining to, derived from, or resembling bone marrow or the spinal cord.
2. having the appearance of myelocytes, but not derived from bone marrow. cell lines. Gastroenterology 2000; 119:310-322.
(46.) Vidrich A, Lee J, James E, Cobb L Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, Type 1 autoimmune hepatitis, sad primary aclerosing cholangitis. J. of Clin. Imm. 1995: 15(6):293-299.
(47.) Hardarson s, LaBrecque DR, Mitros PA, Neil GA, and Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High Prevalence in Ulcerative Colitis. Primary Sclerosing Cholangitis. and Autoimmune Hepatitis. Am. J. of Clin. Path. 1993: 99:277-281.
(48.) Vasiliauskas EA, Plevy SE, Landers CJ. Binder SW, Ferguson DM, Yang H, Rotter Jl, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 199: 110:1810-1819.
(49.) Boyum A. Separation of leucocytes from blood and bone marrow. Scand. J. Clin Lab Invest. 1968; 21:31-50.
(50.) Chowdhury SM. Broomhead V, Spickett GP. Pitfalls of formalin fixation for determination of anti-neutrophilic cytoplasmic antibodies. J. Clin Path 1999; 52:475-477.
(51.) Lock RJ. Detection of auto-antibodies to neutrophil cytoplasmic antigens. J. Clin Path. 1994: 47:4-8.
(52.) Lee SS, Lawson JWM JWM Joe's Window Manager
JWM Journal of Wildlife Management , Chak W: Distinction between antinuclear antibody and pANCA. J Clin Path 1991: 44:962-963.
(53.) Spockett EP Bronhead V: Formalin fixation and patterns of antineutrophil cytoplasmic antibodies. J Clin Path 1995.48:36-39.
(54.) Rose S, Lentz J, Walsh M: Clinical evaluation of a new immunodiagnostic immunodiagnostic
pertaining to diagnosis by immune reactions. assay system for inflammatory bowel disease. Am J. of Gastro 1998; 93(9)A597.
(55.) Sandborn WJ, Loftus EV, Colombel JF, Fleming KA, Seibold F. Homburger HA. Boualem S, Chapman RS. Tremaine WJ, Kaul DK, Wallace J, Harmsen WS. Zinsmeister AR. Targan SR. Evaluation of serologic disease markers in a population based cohort of patients with ulcerative colitis and Crohn's disease. Inf. Bowel Dis 2001; 7:192-201.
Chart CD COHORT ASCA lgA % Cumulative Total Panel+ OmpC+ pANCA+ Detected % Detected Entire Cohort 175 96 54.9% 54.9% ASCA Panel - 79 22 12.6% 67.4% ASCA Penal -/OmpC- 57 15 8.6% 76.0% ASCA Panel-/OmpO- 42 6.0% 76.0% /pAN CA- Total % detected: 76.1% IBD COHORT ASCA lgA % Cumulative Total Panel+ OmpC+ pANCA+ Detected % Detected Entire Cohort 275 104 37.8% 37.8% ASCA Panel 171 32 11.6% 49.5% ASCA Panel -/OmpC- 139 69 25.1% 74.5% ASCA Panel -/OmpC- 70 0.0% 74.5% /pANCA- Total % detected: 74.5% ULCERATIVE COLITIS COHORT ASCA lgA % Cumulative Total Panel+ OmpC+ pANCA+ Detected % Detected Entire Cohort 100 68 68.0% 68.0% pANCA neg 32 2 2.0% 70.0% pANCA -/OmpC- 30 2 2% 72.0% pANCA -/OmpC- 28 0.0% 72.0% Total % detected: 72.0% NORMAL, IBS, DISEASE CONTROLS ASCA lgA % Cumulative Total Panel+ OmpC+ pANCA+ Detected % Detected Entire Cohort- 127 1 0.8% 0.8% ASCA Panel - 126 3 2.4% 3.1% ASCA Panel -/OmpC- 123 4 3.1% 6.3% ASCA Panel -/OmpC- 119 0.0% 6.3% /pANCA- Total % detected: 6.3%